www.TheFinancialMarketingGroup.com
Followers | 59 |
Posts | 2,197 |
Boards Moderated | 4 |
Alias Born | 04/28/2019 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
INMB is our fresh Nasdaq Stock Alert set for huge reversal trade
=====================
INmune Bio Inc. (INMB)
Alert Price: $8.82
Float: 2.82M
Corporate Presentation
Fact Sheet
12-Month Consensus Price Target: $13.00 (Maxim Group)
Website | Recent News
========================
Members,
July was one of our most profitable months of 2019.
We delivered 6 solid winners in a row for a grand total of +270% in realistic gains!
We now plan to kickoff the month of August with what could be one of our biggest long-term winners yet.
Just like two of our most recent winners, the Company trades on the NASDAQ exchange and has tremendous growth potential.
Please turn your immediate attention to INmune Bio Inc. (INMB).
INMB is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s.
INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine.
INMB's therapies provide treatment for diseases that effect millions of patients each year.
Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026.
Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result.
Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer ( NK ) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit http://www.inmunebio.com.
INMB Pipeline
INKmune-Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune.
INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments.
XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death.
INMB's Pipeline's Multi-Billion Dollar Market Opportunity
• XPro1595 - Alzheimer’s/dementia market*
– 5.8 M patients in US
– 2019 est cost to care for US AD patients $280B
• INKmune
- Cancer residual disease market **
– 1,735,350 new cases and 609,640 people will die
– Initial targets: Ovarian Cancer and High Risk MDS
• INB03
- Resistance to Checkpoint Inhibitors market***
– CPI’s work 27% of patients. CPI 2025 est market size $56B
– INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer
All three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term.
INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19
INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19
INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20
XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19
INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20
XPro1595 UK Alzheimer’s Early Data - Q1’20
INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20
INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20
The Alzheimer Association believes in IMNB
In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association.
The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks.
This ringing endorsement from the Alzheimer Association should have potential investors sold on IMNB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone.
The Smart Money Is Buying Up Shares In IMNB
Insiders own 63% of the outstanding shares of INMB.
Insiders have spent $770,000 buying up company shares in the past two months.
The Company has zero debt!
The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential.
Who would know better if the Company was undervalued than those working within.
Tiny Float = Big Move Potential
The public float for IMNB is just 2.98M
A float that low is a rarity for companies listed on the NASDAQ.
It also means the IMNB could moonshot if it were to see an increase in daily volume .
In fact, the first time IMNB broke over 100K in daily volume , its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%!
INMB Trades Under $9 And Has A $13 Price Target
In March, Maxim Group launched coverage of INMB with a “buy” rating and $13 price target.
Analyst Jason McCarthy stated that INB03, a selective TNF inhibitor downregulates the immunosuppressive factors found in the tumor microenvironment, turning cold tumors hot. An open-label Phase 1 study is ongoing, with data expected in the second quarter of 2019.
He said XPro1595 selectively targets the soluble form of TNF and may inhibit activated microglia, a type of innate immune cell, representing a differentiated approach, compared with targeting beta amyloid or tau.
XPro1595’s preclinical data has been positive, he said, and a Phase 1 study is scheduled to start in the second quarter of 2019. Also initiating in the second quarter of 2019 is a Phase 1/2 study of INKmune, a modified tumor cell line that primes existing natural killer cells.
“Innate immunity is a space that continues to evolve and rise behind CAR-T and checkpoints (both target adaptive immunity), with multiple players in the space, including big pharma/biotech,” Mr. McCarthy said. “INmune's programs should report data in 2019 providing catalysts for the stock to support a higher valuation,” he added.
With an upside of over +47%, now could be the perfect time to start building a position in INMB.
Recent Developments
INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit
This week, RJ Tesi, M.D., co-founder and CEO , will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit.
We will be keeping a close eye on this, as any data that comes out could serve as a strong bullish catalyst for INMB's share price.
Technical Analysis
We've done our very own chart analysis on INMB, and we the potential for a move of over 21%!
The stock has seen multiple bounces and reversals from these levels, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal.
The Bottom-Line
We don't think INMB will be trading under the radar for much longer.
Any positive data released by the Company could grab the attention of Wall St .
With its low-float, INMB could see a huge run-up.
ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources for a 1-day investor relations advertising marketing campaign w/ 1500 TradingView™ views for INMB. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
INMB is our fresh Nasdaq Stock Alert set for huge reversal trade
=====================
INmune Bio Inc. (INMB)
Alert Price: $8.82
Float: 2.82M
Corporate Presentation
Fact Sheet
12-Month Consensus Price Target: $13.00 (Maxim Group)
Website | Recent News
========================
Members,
July was one of our most profitable months of 2019.
We delivered 6 solid winners in a row for a grand total of +270% in realistic gains!
We now plan to kickoff the month of August with what could be one of our biggest long-term winners yet.
Just like two of our most recent winners, the Company trades on the NASDAQ exchange and has tremendous growth potential.
Please turn your immediate attention to INmune Bio Inc. (INMB).
INMB is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s.
INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine.
INMB's therapies provide treatment for diseases that effect millions of patients each year.
Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026.
Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result.
Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer ( NK ) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit http://www.inmunebio.com.
INMB Pipeline
INKmune-Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune.
INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments.
XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death.
INMB's Pipeline's Multi-Billion Dollar Market Opportunity
• XPro1595 - Alzheimer’s/dementia market*
– 5.8 M patients in US
– 2019 est cost to care for US AD patients $280B
• INKmune
- Cancer residual disease market **
– 1,735,350 new cases and 609,640 people will die
– Initial targets: Ovarian Cancer and High Risk MDS
• INB03
- Resistance to Checkpoint Inhibitors market***
– CPI’s work 27% of patients. CPI 2025 est market size $56B
– INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer
All three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term.
INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19
INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19
INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20
XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19
INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20
XPro1595 UK Alzheimer’s Early Data - Q1’20
INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20
INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20
The Alzheimer Association believes in IMNB
In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association.
The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks.
This ringing endorsement from the Alzheimer Association should have potential investors sold on IMNB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone.
The Smart Money Is Buying Up Shares In IMNB
Insiders own 63% of the outstanding shares of INMB.
Insiders have spent $770,000 buying up company shares in the past two months.
The Company has zero debt!
The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential.
Who would know better if the Company was undervalued than those working within.
Tiny Float = Big Move Potential
The public float for IMNB is just 2.98M
A float that low is a rarity for companies listed on the NASDAQ.
It also means the IMNB could moonshot if it were to see an increase in daily volume .
In fact, the first time IMNB broke over 100K in daily volume , its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%!
INMB Trades Under $9 And Has A $13 Price Target
In March, Maxim Group launched coverage of INMB with a “buy” rating and $13 price target.
Analyst Jason McCarthy stated that INB03, a selective TNF inhibitor downregulates the immunosuppressive factors found in the tumor microenvironment, turning cold tumors hot. An open-label Phase 1 study is ongoing, with data expected in the second quarter of 2019.
He said XPro1595 selectively targets the soluble form of TNF and may inhibit activated microglia, a type of innate immune cell, representing a differentiated approach, compared with targeting beta amyloid or tau.
XPro1595’s preclinical data has been positive, he said, and a Phase 1 study is scheduled to start in the second quarter of 2019. Also initiating in the second quarter of 2019 is a Phase 1/2 study of INKmune, a modified tumor cell line that primes existing natural killer cells.
“Innate immunity is a space that continues to evolve and rise behind CAR-T and checkpoints (both target adaptive immunity), with multiple players in the space, including big pharma/biotech,” Mr. McCarthy said. “INmune's programs should report data in 2019 providing catalysts for the stock to support a higher valuation,” he added.
With an upside of over +47%, now could be the perfect time to start building a position in INMB.
Recent Developments
INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit
This week, RJ Tesi, M.D., co-founder and CEO , will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit.
We will be keeping a close eye on this, as any data that comes out could serve as a strong bullish catalyst for INMB's share price.
Technical Analysis
We've done our very own chart analysis on INMB, and we the potential for a move of over 21%!
The stock has seen multiple bounces and reversals from these levels, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal.
The Bottom-Line
We don't think INMB will be trading under the radar for much longer.
Any positive data released by the Company could grab the attention of Wall St .
With its low-float, INMB could see a huge run-up.
ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources for a 1-day investor relations advertising marketing campaign w/ 1500 TradingView™ views for INMB. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
BTN - Trend Momentum Is Strong With BULLS
Ballantyne Strong , Inc. is a holding company. The Company's business activities focus on serving the cinema, retail, financial and government markets. The Company and its subsidiaries design, integrate and install technology solutions for a range of applications; develop and deliver out-of-home messaging, advertising and communications; manufacture projection screens, and provide managed services, including monitoring of networked equipment to its customers. The Company operates through two segments: Cinema and Digital Media. Its Cinema operations include the sale of digital projection equipment, screens and sound systems. Its Digital Media operations include the delivery of end-to-end digital signage solutions, video communication solutions, content creation, and management and service of digital signage and digital cinema equipment. The Company's products are distributed to the retail, financial, government and cinema markets throughout the world.
SHORT INTEREST
17.29K 07/15/19
P/E Current
-3.87
P/E Ratio (with extraordinary items)
-3.75
BTN - Trend Momentum Is Strong With BULLS
Ballantyne Strong , Inc. is a holding company. The Company's business activities focus on serving the cinema, retail, financial and government markets. The Company and its subsidiaries design, integrate and install technology solutions for a range of applications; develop and deliver out-of-home messaging, advertising and communications; manufacture projection screens, and provide managed services, including monitoring of networked equipment to its customers. The Company operates through two segments: Cinema and Digital Media. Its Cinema operations include the sale of digital projection equipment, screens and sound systems. Its Digital Media operations include the delivery of end-to-end digital signage solutions, video communication solutions, content creation, and management and service of digital signage and digital cinema equipment. The Company's products are distributed to the retail, financial, government and cinema markets throughout the world.
SHORT INTEREST
17.29K 07/15/19
P/E Current
-3.87
P/E Ratio (with extraordinary items)
-3.75
BIG 5 Aiming For 40% Push From Floor
Big 5 Sporting Goods Corporation is a sporting goods retailer in the western United States. The Company offers a range of products in a sporting goods store format. The Company also offers products online through its e-commerce platform. The Company's product mix includes athletic shoes, apparel and accessories, as well as a range of outdoor and athletic equipment for team sports, fitness, camping, hunting, fishing, tennis, golf, winter and summer recreation, and roller sports. The Company purchases merchandise from sporting goods equipment, athletic footwear and apparel manufacturers. It offers various brands, such as adidas, Coleman, Footjoy, JanSport, Rawlings, Spalding, Asics, Columbia, Franklin , Lifetime, Razor, Speedo, Bearpaw, Crocs , Gildan, Mizuno, Rollerblade and Timex . The Company operated 432 stores and an e-commerce platform under the name Big 5 Sporting Goods , as of January 1, 2017.
SHORT INTEREST
5.55M 07/15/19
P/E
Current
-12.42
P/E Ratio (with extraordinary items)
-156.70
BIG 5 Aiming For 40% Push From Floor
Big 5 Sporting Goods Corporation is a sporting goods retailer in the western United States. The Company offers a range of products in a sporting goods store format. The Company also offers products online through its e-commerce platform. The Company's product mix includes athletic shoes, apparel and accessories, as well as a range of outdoor and athletic equipment for team sports, fitness, camping, hunting, fishing, tennis, golf, winter and summer recreation, and roller sports. The Company purchases merchandise from sporting goods equipment, athletic footwear and apparel manufacturers. It offers various brands, such as adidas, Coleman, Footjoy, JanSport, Rawlings, Spalding, Asics, Columbia, Franklin , Lifetime, Razor, Speedo, Bearpaw, Crocs , Gildan, Mizuno, Rollerblade and Timex . The Company operated 432 stores and an e-commerce platform under the name Big 5 Sporting Goods , as of January 1, 2017.
SHORT INTEREST
5.55M 07/15/19
P/E
Current
-12.42
P/E Ratio (with extraordinary items)
-156.70
ACTG - Huge Breakout. Can It Start Bull Momentum?
Acacia Research Corporation, through its subsidiaries, invests in, licenses and enforces patented technologies. The Company's operating subsidiaries partner with inventors and patent owners, applying their legal and technology expertise to patent assets to unlock the financial value in their patented inventions. The Company's operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. The Company's operating subsidiaries own or control the rights to multiple patent portfolios, which include the United States patents and certain foreign counterparts, covering technologies used in a range of industries.
172.72K 07/15/19 SHORT INTEREST
P/E Current
-1.31
P/E Ratio (with extraordinary items)
-1.76
ACTG - Huge Breakout. Can It Start Bull Momentum?
Acacia Research Corporation, through its subsidiaries, invests in, licenses and enforces patented technologies. The Company's operating subsidiaries partner with inventors and patent owners, applying their legal and technology expertise to patent assets to unlock the financial value in their patented inventions. The Company's operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. The Company's operating subsidiaries own or control the rights to multiple patent portfolios, which include the United States patents and certain foreign counterparts, covering technologies used in a range of industries.
172.72K 07/15/19 SHORT INTEREST
P/E Current
-1.31
P/E Ratio (with extraordinary items)
-1.76
ALJJ - Strong Trend - Could Go A lot Higher
ALJ Regional Holdings , Inc. is a holding company. The Company's segments include Faneuil, Inc. (Faneuil), Floors-N-More, LLC (Carpets) and Phoenix Color Corp. (Phoenix). The Faneuil segment provides business processing solutions for a client portfolio that includes both commercial and government entities across several verticals, including transportation, government services, utilities and healthcare. Faneuil delivers outsourcing support, ranging from customer contact centers, fulfillment operations and information technology services, to manual and electronic toll collection, violation processing and medical device tracking. The Carpets segment provides multiple products for the commercial, retail and home builder markets, including flooring, countertops, cabinets, window coverings and garage/closet organizers. The Phoenix segment manufactures book components, educational materials and related products.
SHORT INTEREST
33.01K 07/15/19
P/E Current
-9.14
P/E Ratio (with extraordinary items)
-124.81
Be patient with this, expect it to come down first. Buy close to the trendline .
ALJJ - Strong Trend - Could Go A lot Higher
ALJ Regional Holdings , Inc. is a holding company. The Company's segments include Faneuil, Inc. (Faneuil), Floors-N-More, LLC (Carpets) and Phoenix Color Corp. (Phoenix). The Faneuil segment provides business processing solutions for a client portfolio that includes both commercial and government entities across several verticals, including transportation, government services, utilities and healthcare. Faneuil delivers outsourcing support, ranging from customer contact centers, fulfillment operations and information technology services, to manual and electronic toll collection, violation processing and medical device tracking. The Carpets segment provides multiple products for the commercial, retail and home builder markets, including flooring, countertops, cabinets, window coverings and garage/closet organizers. The Phoenix segment manufactures book components, educational materials and related products.
SHORT INTEREST
33.01K 07/15/19
P/E Current
-9.14
P/E Ratio (with extraordinary items)
-124.81
Be patient with this, expect it to come down first. Buy close to the trendline .
MLSS - Bullish Momentum + Increasing Volume
Milestone Scientific Inc . ( Milestone ) is engaged in providing computer-controlled injection technologies and solutions for the medical and dental markets. The Company uses its CompuFlo technology for the delivery of medicaments. The CompuFlo pressure or force Computer-Controlled Local Anesthetic Delivery (C-CLAD) technology is a medical technology for the delivery of drugs, anesthetics and other medicaments into various tissue types. Milestone's product portfolio includes Single Tooth Anesthesia Instrument (STA Instrument), CompuDent, CompuMed and The Wand. The Company's STA Instrument is a computer-controlled local anesthesia delivery instrument that utilizes the pressure feedback elements of Milestone's CompuFlo technology. CompuDent (also known as the Wand Plus internationally) is Milestone's C-CLAD instrument. CompuMed is a computer-controlled injection instrument offered by the Company. The Wand handpiece is used in conjunction with the STA, CompuDent and CompuMed instruments.
SHORT INTEREST
372.92K 07/15/19
P/E Current
-2.07
P/E Ratio (with extraordinary items)
-2.79
Average Recommendation: BUY
Average Target Price: 1.0
MLSS - Bullish Momentum + Increasing Volume
Milestone Scientific Inc . ( Milestone ) is engaged in providing computer-controlled injection technologies and solutions for the medical and dental markets. The Company uses its CompuFlo technology for the delivery of medicaments. The CompuFlo pressure or force Computer-Controlled Local Anesthetic Delivery (C-CLAD) technology is a medical technology for the delivery of drugs, anesthetics and other medicaments into various tissue types. Milestone's product portfolio includes Single Tooth Anesthesia Instrument (STA Instrument), CompuDent, CompuMed and The Wand. The Company's STA Instrument is a computer-controlled local anesthesia delivery instrument that utilizes the pressure feedback elements of Milestone's CompuFlo technology. CompuDent (also known as the Wand Plus internationally) is Milestone's C-CLAD instrument. CompuMed is a computer-controlled injection instrument offered by the Company. The Wand handpiece is used in conjunction with the STA, CompuDent and CompuMed instruments.
SHORT INTEREST
372.92K 07/15/19
P/E Current
-2.07
P/E Ratio (with extraordinary items)
-2.79
Average Recommendation: BUY
Average Target Price: 1.0
AMS - 209 Day Bullish Trend Representing Company Growth
American Shared Hospital Services engages in leasing radiosurgery and radiation therapy equipment to healthcare providers. Its equipment includes Gamma Knife, PBRT, and IGRT. It operates through Medical Services segment. The company was founded by Ernest A. Bates in 1977 and is headquartered in San Francisco, CA.
SHORT INTEREST
6.66K 07/15/19
P/E Current
17.28
P/E Ratio (with extraordinary items)
19.69
P/E Ratio (without extraordinary items)
13.62
AMS - 209 Day Bullish Trend Representing Company Growth
American Shared Hospital Services engages in leasing radiosurgery and radiation therapy equipment to healthcare providers. Its equipment includes Gamma Knife, PBRT, and IGRT. It operates through Medical Services segment. The company was founded by Ernest A. Bates in 1977 and is headquartered in San Francisco, CA.
SHORT INTEREST
6.66K 07/15/19
P/E Current
17.28
P/E Ratio (with extraordinary items)
19.69
P/E Ratio (without extraordinary items)
13.62
Can XRP Break Through EMA To Go Beyond $0.31
It has been a tough hold if you have been investing in XRP over the past few months. In satoshi value it has struggled but even in USD when other coins have had more success, XRP has remained stable.
Still appears to be stuck in a zone it has been stable in for over 6 months now. It needs a push. It feels like it is being held back.
Can XRP Break Through EMA To Go Beyond $0.31
It has been a tough hold if you have been investing in XRP over the past few months. In satoshi value it has struggled but even in USD when other coins have had more success, XRP has remained stable.
Still appears to be stuck in a zone it has been stable in for over 6 months now. It needs a push. It feels like it is being held back.
ETH - First Step Of Retracement Complete - Can It Climb More?
ETH looking bullish . Posted about this on the 28th. Mapped out some targets and with the bullish nature of Bitcoin the USD pairing of ETH has hit the first target well.
More importantly how much momentum does it have to carry on going and reclaim some of those losses.
ETH - First Step Of Retracement Complete - Can It Climb More?
ETH looking bullish . Posted about this on the 28th. Mapped out some targets and with the bullish nature of Bitcoin the USD pairing of ETH has hit the first target well.
More importantly how much momentum does it have to carry on going and reclaim some of those losses.
INMB is our fresh Nasdaq Stock Alert set for huge reversal trade
=====================
INmune Bio Inc. (INMB)
Alert Price: $8.82
Float: 2.82M
Corporate Presentation
Fact Sheet
12-Month Consensus Price Target: $13.00 (Maxim Group)
Website | Recent News
========================
Members,
July was one of our most profitable months of 2019.
We delivered 6 solid winners in a row for a grand total of +270% in realistic gains!
We now plan to kickoff the month of August with what could be one of our biggest long-term winners yet.
Just like two of our most recent winners, the Company trades on the NASDAQ exchange and has tremendous growth potential.
Please turn your immediate attention to INmune Bio Inc. (INMB).
INMB is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s.
INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine.
INMB's therapies provide treatment for diseases that effect millions of patients each year.
Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026.
Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result.
Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer ( NK ) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit http://www.inmunebio.com.
INMB Pipeline
INKmune-Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune.
INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments.
XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death.
INMB's Pipeline's Multi-Billion Dollar Market Opportunity
• XPro1595 - Alzheimer’s/dementia market*
– 5.8 M patients in US
– 2019 est cost to care for US AD patients $280B
• INKmune
- Cancer residual disease market **
– 1,735,350 new cases and 609,640 people will die
– Initial targets: Ovarian Cancer and High Risk MDS
• INB03
- Resistance to Checkpoint Inhibitors market***
– CPI’s work 27% of patients. CPI 2025 est market size $56B
– INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer
All three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term.
INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19
INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19
INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20
XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19
INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20
XPro1595 UK Alzheimer’s Early Data - Q1’20
INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20
INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20
The Alzheimer Association believes in IMNB
In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association.
The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks.
This ringing endorsement from the Alzheimer Association should have potential investors sold on IMNB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone.
The Smart Money Is Buying Up Shares In IMNB
Insiders own 63% of the outstanding shares of INMB.
Insiders have spent $770,000 buying up company shares in the past two months.
The Company has zero debt!
The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential.
Who would know better if the Company was undervalued than those working within.
Tiny Float = Big Move Potential
The public float for IMNB is just 2.98M
A float that low is a rarity for companies listed on the NASDAQ.
It also means the IMNB could moonshot if it were to see an increase in daily volume .
In fact, the first time IMNB broke over 100K in daily volume , its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%!
INMB Trades Under $9 And Has A $13 Price Target
In March, Maxim Group launched coverage of INMB with a “buy” rating and $13 price target.
Analyst Jason McCarthy stated that INB03, a selective TNF inhibitor downregulates the immunosuppressive factors found in the tumor microenvironment, turning cold tumors hot. An open-label Phase 1 study is ongoing, with data expected in the second quarter of 2019.
He said XPro1595 selectively targets the soluble form of TNF and may inhibit activated microglia, a type of innate immune cell, representing a differentiated approach, compared with targeting beta amyloid or tau.
XPro1595’s preclinical data has been positive, he said, and a Phase 1 study is scheduled to start in the second quarter of 2019. Also initiating in the second quarter of 2019 is a Phase 1/2 study of INKmune, a modified tumor cell line that primes existing natural killer cells.
“Innate immunity is a space that continues to evolve and rise behind CAR-T and checkpoints (both target adaptive immunity), with multiple players in the space, including big pharma/biotech,” Mr. McCarthy said. “INmune's programs should report data in 2019 providing catalysts for the stock to support a higher valuation,” he added.
With an upside of over +47%, now could be the perfect time to start building a position in INMB.
Recent Developments
INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit
This week, RJ Tesi, M.D., co-founder and CEO , will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit.
We will be keeping a close eye on this, as any data that comes out could serve as a strong bullish catalyst for INMB's share price.
Technical Analysis
We've done our very own chart analysis on INMB, and we the potential for a move of over 21%!
The stock has seen multiple bounces and reversals from these levels, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal.
The Bottom-Line
We don't think INMB will be trading under the radar for much longer.
Any positive data released by the Company could grab the attention of Wall St .
With its low-float, INMB could see a huge run-up.
ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources for a 1-day investor relations advertising marketing campaign w/ 1500 TradingView™ views for INMB. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
INMB is our fresh Nasdaq Stock Alert set for huge reversal trade
=====================
INmune Bio Inc. (INMB)
Alert Price: $8.82
Float: 2.82M
Corporate Presentation
Fact Sheet
12-Month Consensus Price Target: $13.00 (Maxim Group)
Website | Recent News
========================
Members,
July was one of our most profitable months of 2019.
We delivered 6 solid winners in a row for a grand total of +270% in realistic gains!
We now plan to kickoff the month of August with what could be one of our biggest long-term winners yet.
Just like two of our most recent winners, the Company trades on the NASDAQ exchange and has tremendous growth potential.
Please turn your immediate attention to INmune Bio Inc. (INMB).
INMB is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s.
INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine.
INMB's therapies provide treatment for diseases that effect millions of patients each year.
Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026.
Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result.
Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer ( NK ) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit http://www.inmunebio.com.
INMB Pipeline
INKmune-Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune.
INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments.
XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death.
INMB's Pipeline's Multi-Billion Dollar Market Opportunity
• XPro1595 - Alzheimer’s/dementia market*
– 5.8 M patients in US
– 2019 est cost to care for US AD patients $280B
• INKmune
- Cancer residual disease market **
– 1,735,350 new cases and 609,640 people will die
– Initial targets: Ovarian Cancer and High Risk MDS
• INB03
- Resistance to Checkpoint Inhibitors market***
– CPI’s work 27% of patients. CPI 2025 est market size $56B
– INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer
All three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term.
INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19
INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19
INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20
XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19
INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20
XPro1595 UK Alzheimer’s Early Data - Q1’20
INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20
INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20
The Alzheimer Association believes in IMNB
In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association.
The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks.
This ringing endorsement from the Alzheimer Association should have potential investors sold on IMNB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone.
The Smart Money Is Buying Up Shares In IMNB
Insiders own 63% of the outstanding shares of INMB.
Insiders have spent $770,000 buying up company shares in the past two months.
The Company has zero debt!
The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential.
Who would know better if the Company was undervalued than those working within.
Tiny Float = Big Move Potential
The public float for IMNB is just 2.98M
A float that low is a rarity for companies listed on the NASDAQ.
It also means the IMNB could moonshot if it were to see an increase in daily volume .
In fact, the first time IMNB broke over 100K in daily volume , its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%!
INMB Trades Under $9 And Has A $13 Price Target
In March, Maxim Group launched coverage of INMB with a “buy” rating and $13 price target.
Analyst Jason McCarthy stated that INB03, a selective TNF inhibitor downregulates the immunosuppressive factors found in the tumor microenvironment, turning cold tumors hot. An open-label Phase 1 study is ongoing, with data expected in the second quarter of 2019.
He said XPro1595 selectively targets the soluble form of TNF and may inhibit activated microglia, a type of innate immune cell, representing a differentiated approach, compared with targeting beta amyloid or tau.
XPro1595’s preclinical data has been positive, he said, and a Phase 1 study is scheduled to start in the second quarter of 2019. Also initiating in the second quarter of 2019 is a Phase 1/2 study of INKmune, a modified tumor cell line that primes existing natural killer cells.
“Innate immunity is a space that continues to evolve and rise behind CAR-T and checkpoints (both target adaptive immunity), with multiple players in the space, including big pharma/biotech,” Mr. McCarthy said. “INmune's programs should report data in 2019 providing catalysts for the stock to support a higher valuation,” he added.
With an upside of over +47%, now could be the perfect time to start building a position in INMB.
Recent Developments
INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit
This week, RJ Tesi, M.D., co-founder and CEO , will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit.
We will be keeping a close eye on this, as any data that comes out could serve as a strong bullish catalyst for INMB's share price.
Technical Analysis
We've done our very own chart analysis on INMB, and we the potential for a move of over 21%!
The stock has seen multiple bounces and reversals from these levels, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal.
The Bottom-Line
We don't think INMB will be trading under the radar for much longer.
Any positive data released by the Company could grab the attention of Wall St .
With its low-float, INMB could see a huge run-up.
ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources for a 1-day investor relations advertising marketing campaign w/ 1500 TradingView™ views for INMB. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Bull Trap? Bitcoin To Drop?
Lower volume is showing possible fake price action with a possible bull trap in play.
I'd be very careful over the next few days with this. We believe a possible drop due to a rejection here because the volume has been a lot lower than previous rallies. However, a surge could create a FOMO rally back up to 11K + levels.
Bull Trap? Bitcoin To Drop?
Lower volume is showing possible fake price action with a possible bull trap in play.
I'd be very careful over the next few days with this. We believe a possible drop due to a rejection here because the volume has been a lot lower than previous rallies. However, a surge could create a FOMO rally back up to 11K + levels.
LINK BOUNCED 20% WILL IT CARRY ON?
We spoke about Chainlink a while back that it was in a mega bearish trend and it would bounce and when it did it would be hard. It bounced over 20% in a couple of candles from a 1:1 retracement on the Fibonacci.
This is a perfect lesson for people buying into hype and waiting for the perfect entry point on a reversal. Momentum is key.
LINK BOUNCED 20% WILL IT CARRY ON?
We spoke about Chainlink a while back that it was in a mega bearish trend and it would bounce and when it did it would be hard. It bounced over 20% in a couple of candles from a 1:1 retracement on the Fibonacci.
This is a perfect lesson for people buying into hype and waiting for the perfect entry point on a reversal. Momentum is key.
HMPQ is our new & exciting sub-penny CBD alert for tomorrow.
=====================
HempAmericana, Inc (HMPQ)
Alert Price: $0.0007
Website | Recent News
========================
Members,
We are coming off and incredible week of trading.
Last Thursday's alert broke out huge on on Friday, giving our members ample time to secure up to +76% in realistic profit.
This was our 4th winning trade alert in a row.
All in all, our members have had the opportunity to secure up to +225% in realistic profit in just about two weeks time.
We plan on keeping the good times rolling with a fresh trade idea that has the potential to double in price.
Please turn your immediate attention to HempAmericana, Inc (HMPQ).
Just like our most recent winners, HMPQ is sitting on a bottom'd out chart with plenty of room to the upside.
We've had a lot of success in the cannabis sector, our last pick in this space more than doubled in price in a very short amount of time.
HMPQ is quite enticing at the moment, as there are not many companies in the CBD sector trading for less than a penny.
And if there are, it is unlikely that they own and operate a high-capacity, state-of-the-art CBD extraction and processing facility like HMPQ does.
This is an exciting time for HMPQ shareholders, as the Company is witnessing quite the growth period.
Management recently updated shareholders on current inventory levels on hand for premium-quality CBD products. As of July 15, 2019, the Company holds CBD-based product inventories in excess of $500,000 based on current market pricing for end-market sales of comparable products. This inventory represents production over the past 60 days and includes CBD Extract, Crude CBD Oil , CBD Distillate, and bottled CBD Tincture.
Management believes it will improve margins over time as production smooths out and the volume absorbs fixed operating cost.
This is the kind of news we like to hear.
Wall St . loves nothing more than healthy margins and revenue growth.
It appears that we have found another gem in the CBD space with HMPQ.
We are urging all of our members to start their research on HMPQ immediately, and consider building a position tomorrow morning at 9:30AM EST.
About HempAmericana, Inc.
HempAmericana is an emerging participant in the CBD products market. The Company owns and operates a high-capacity, state-of-the-art CBD extraction and processing facility located in Augusta, Maine. This facility is armed with a supersized supercritical CO2 extraction system, centrifugal partition chromatography refinement technology, and a mechanized fully-automated CBD bottling system. The Company’s CBD oil business uses the brand designation, “Weed Got Oil”. HempAmericana also researches, develops, and sells products made of industrial hemp, including a popular brand of hemp rolling papers marketed under the brand name, “Rolling Thunders”. See more at http://www.hempamericana.com.
This Is An Exciting Time To Be A HMPQ Shareholder
In a recent corporate update CEO Salvador Rosillo painted a picture of a company gearing up for an amazing 2nd half of 2018.
Highlights Include:
A new relationship with Eagle Hemp of Florida (“Eagle Hemp”), located in the West Palm Beach area. This relationship now comprises an initial large purchase order and a clear path for a continuing series of purchase orders set to roll out over coming months and quarters.
Vaping machine is active and fully operational, they are now ready to produce and sell CBD vapes.
Plans to build a greenhouse dedicated to cultivating super-enriched seeds.
Improved margins
Please feel free to read the entire letter to shareholders below, we think you'll be just as impressed as we are.
Dear Valued Shareholder,
As we begin to establish growing momentum in our core CBD Oil production and distribution business, I wanted to take this opportunity to express our gratitude for your commitment and loyalty to our long-term value proposition and to discuss our current opportunities and our roadmap as we gear up to execute on the powerful opportunities that lie ahead.
As you know, we have commenced bottling 500mg and 1000mg full-spectrum CBD distillate in our state-of-the-art CBD extraction and production facility in Augusta, Maine. Our inaugural production expectations are set at production of 2,000 bottles per day with a gradual increase to 8,000 bottles per day to fill demand. We already have over 50,000 bottles of full-spectrum distillate bottled and ready to ship with tens of thousands to follow.
We are also bottling a 250mg potency, which is perfect for the CBD-for-pets market. And, on the high end, we are also bottling 2500mg and 5000mg strengths, but we can replicate any formula.
Much of this production will be distributed under our proprietary brand, “Weed Got Oil”. But we are also actively pursuing a major place in the white label market for premium full-spectrum distillate CBD oil . There are over 400 brands now in the CBD space, and most of them turn to a major high-capacity producer, like HempAmericana, to build up an inventory of product.
For example, we recently announced a new relationship with Eagle Hemp of Florida (“Eagle Hemp”), located in the West Palm Beach area. This relationship now comprises an initial large purchase order and a clear path for a continuing series of purchase orders set to roll out over coming months and quarters.
The terms of the deal provide a window into the framework we have been working toward as we leverage our capital investments in our Augusta facility for the white label opportunity. We are set to receive strong demand at strong terms, including compensation for high-volume production of our premium CBD Oil output as well as our bottling technology.
In all, just in the first of these planned orders, we will receive a substantial revenue input, with no costs associated with bottling, labeling, or shipping of the final product.
Eagle Hemp is just one of many customers currently in play for our premium product output. The CBD market is turning out to be every bit the juggernaut that the major analyst firms have been suggesting over the past year. Estimates now range from several hundred to several thousand percentage points of gross sales expansion in the space over the next 36-48 months, which is a reasonable definition of boom conditions for a major industry in robust infancy.
The driver here, as we have elaborated in past communications, is about the seemingly bottomless demand growth function that accompanies the evolution of a product category from fringe consumer niche to mainstream adoption.
It is also important to note that we continue to receive requests from other industry customers and we are in the process of investigating the credibility of such requests and in negotiating similar terms for concrete relationships.
In addition, our production facility and lab are running along in amazing fashion. We now have two bottling machines active and operational due to the tremendous interest coming in the door. Once we have distilled this interest into official purchase orders, we will divulge them in our communications.
We also want to announce that our vaping machine is active and fully operational, we are now ready to produce and sell CBD vapes.
Finally, as we continue to expand, diversify, and integrate, we are now also working on plans to build a greenhouse dedicated to cultivating super-enriched seeds. We have always been committed to the long-term goal of fully controlling our production ecosystem from seed to product, and this is the next step in establishing that fully vertical model, where we see the strongest margins.
Best Regards,
Salvador Rosillo
As you can see, this is a company built for growth, and at just $0.007 per share, this could be one of the biggest steals in the entire cannabis sector.
Market Outlook for CBD:
New projections from the Brightfield Group in its June report suggest, if anything, a further acceleration in the overall growth of the CBD space, and some suggestion that this acceleration is being driven by an increasingly tangible jump in mainstream consumer adoption of CBD-based products. Specifically, the report notes that 2019 will show a 700% jump relative to 2018 levels for all domestic sales of CBD-based products, with 2019 on pace to exceed $5 billion in total sales of products containing CBD given current data. In addition, according to the Brightfield Group researchers, much of this jump will be due to sales in mainstream retail chain stores.
The cannabis market has grown at a tremendous pace over the recent years and as such, the industry has established itself a major global market. According to data compiled by Grand View Research, the global legal cannabis market is projected to reach USD 146.4 Billion by the 2025. It is also expected to grow at a CAGR of 34.6%. The market itself is witnessing a widespread legalization movement due to the growing adoption of the plant within the medical sector. Cannabis is being used heavily around the global for medical applications and treatments for maladies such as cancer, mental disorders, chronic pain, and others. However, the recreational market is thriving as well due specifically to the U.S. and Canada. States like California, Colorado, and Nevada are expected to propel the recreational sector forward at an encouraging rate.
The acceleration of research and development has led to new products within the market, enhancing consumer experiences. The research suggests that the industry is expecting strong exchanges of technological knowledge and information. Meanwhile, as countries like Canada, the U.S., Germany, and Australia lead the market in sales, countries like Israel are focusing on research and technology development to further expand within the industry. Additionally, there are various new forms of technology being introduced into the cannabis sector, such as virtual reality, payment solutions, and medical devices. "That's why we firmly believe that technology stands at the center of the industry's advancement and growth," said Ben Curren Chief Executive Officer of Green Bits, "This innovation will continue to generate market growth, improve public perception, protect public health and safety and enhance the implementation of state programs and regulations.
CBD is becoming widely accepted by consumers and countries. For example, in the U.S., CBD became legal after the Farm Bill that passed in late 2018.
That in mind, consumers could easily find CBD products across the U.S. In turn, we may actually see some CBD companies generating more revenues and earnings than cannabis companies.
Now, investment bank Cowen & Co. analysts estimate that the CBD market will reach $16B by 2025.
That said, CBD companies could experience exponential growth rates with such a large market. Not only that, large-cap drug stores like CVS and Walgreens have bet on CBD .
Additionally, CVS and Walgreens noted they would offer CBD products in more than 2,000 stores across the U.S.
Technical Analysis
Subpenny Stocks = Big Moves
We love these subpenny alerts because even the smallest move can result in massive gains for traders.
As we mentioned above, HMPQ is sitting on a bottom'd out chart with plenty of room to the upside.
We love these type of alerts because the downside risk appears minimal, but the upside is almost too good to ignore.
HMPQ is trading well off its 52-week of $0.0277.
A run back to those levels would net traders nearly +300% in profit from today's alert price.
We've done our very own chart analysis and see the potential for an explosive move in the very near future.
The Bottom-Line
We've been right on the money with our most recent cannabis sector alerts.
HMPQ is exactly the type of alert that we look for. Undervalued with major growth potential.
These are the types of alerts that offer traders the biggest payoff potential.
This could be our next subpenny alert to double in price, so make sure you have it on your radar!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated seventeen thousand five hundred dollars by One 22 Media LLC to conduct a one-day investor relations advertising and marketing campaign and 1,500 Trading View™ views for HMPQ. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Jul 29
Comment: CORRECTION
=====================
HempAmericana, Inc (HMPQ)
Alert Price: $0.007
========================
HMPQ is our new & exciting sub-penny CBD alert for tomorrow.
=====================
HempAmericana, Inc (HMPQ)
Alert Price: $0.0007
Website | Recent News
========================
Members,
We are coming off and incredible week of trading.
Last Thursday's alert broke out huge on on Friday, giving our members ample time to secure up to +76% in realistic profit.
This was our 4th winning trade alert in a row.
All in all, our members have had the opportunity to secure up to +225% in realistic profit in just about two weeks time.
We plan on keeping the good times rolling with a fresh trade idea that has the potential to double in price.
Please turn your immediate attention to HempAmericana, Inc (HMPQ).
Just like our most recent winners, HMPQ is sitting on a bottom'd out chart with plenty of room to the upside.
We've had a lot of success in the cannabis sector, our last pick in this space more than doubled in price in a very short amount of time.
HMPQ is quite enticing at the moment, as there are not many companies in the CBD sector trading for less than a penny.
And if there are, it is unlikely that they own and operate a high-capacity, state-of-the-art CBD extraction and processing facility like HMPQ does.
This is an exciting time for HMPQ shareholders, as the Company is witnessing quite the growth period.
Management recently updated shareholders on current inventory levels on hand for premium-quality CBD products. As of July 15, 2019, the Company holds CBD-based product inventories in excess of $500,000 based on current market pricing for end-market sales of comparable products. This inventory represents production over the past 60 days and includes CBD Extract, Crude CBD Oil , CBD Distillate, and bottled CBD Tincture.
Management believes it will improve margins over time as production smooths out and the volume absorbs fixed operating cost.
This is the kind of news we like to hear.
Wall St . loves nothing more than healthy margins and revenue growth.
It appears that we have found another gem in the CBD space with HMPQ.
We are urging all of our members to start their research on HMPQ immediately, and consider building a position tomorrow morning at 9:30AM EST.
About HempAmericana, Inc.
HempAmericana is an emerging participant in the CBD products market. The Company owns and operates a high-capacity, state-of-the-art CBD extraction and processing facility located in Augusta, Maine. This facility is armed with a supersized supercritical CO2 extraction system, centrifugal partition chromatography refinement technology, and a mechanized fully-automated CBD bottling system. The Company’s CBD oil business uses the brand designation, “Weed Got Oil”. HempAmericana also researches, develops, and sells products made of industrial hemp, including a popular brand of hemp rolling papers marketed under the brand name, “Rolling Thunders”. See more at http://www.hempamericana.com.
This Is An Exciting Time To Be A HMPQ Shareholder
In a recent corporate update CEO Salvador Rosillo painted a picture of a company gearing up for an amazing 2nd half of 2018.
Highlights Include:
A new relationship with Eagle Hemp of Florida (“Eagle Hemp”), located in the West Palm Beach area. This relationship now comprises an initial large purchase order and a clear path for a continuing series of purchase orders set to roll out over coming months and quarters.
Vaping machine is active and fully operational, they are now ready to produce and sell CBD vapes.
Plans to build a greenhouse dedicated to cultivating super-enriched seeds.
Improved margins
Please feel free to read the entire letter to shareholders below, we think you'll be just as impressed as we are.
Dear Valued Shareholder,
As we begin to establish growing momentum in our core CBD Oil production and distribution business, I wanted to take this opportunity to express our gratitude for your commitment and loyalty to our long-term value proposition and to discuss our current opportunities and our roadmap as we gear up to execute on the powerful opportunities that lie ahead.
As you know, we have commenced bottling 500mg and 1000mg full-spectrum CBD distillate in our state-of-the-art CBD extraction and production facility in Augusta, Maine. Our inaugural production expectations are set at production of 2,000 bottles per day with a gradual increase to 8,000 bottles per day to fill demand. We already have over 50,000 bottles of full-spectrum distillate bottled and ready to ship with tens of thousands to follow.
We are also bottling a 250mg potency, which is perfect for the CBD-for-pets market. And, on the high end, we are also bottling 2500mg and 5000mg strengths, but we can replicate any formula.
Much of this production will be distributed under our proprietary brand, “Weed Got Oil”. But we are also actively pursuing a major place in the white label market for premium full-spectrum distillate CBD oil . There are over 400 brands now in the CBD space, and most of them turn to a major high-capacity producer, like HempAmericana, to build up an inventory of product.
For example, we recently announced a new relationship with Eagle Hemp of Florida (“Eagle Hemp”), located in the West Palm Beach area. This relationship now comprises an initial large purchase order and a clear path for a continuing series of purchase orders set to roll out over coming months and quarters.
The terms of the deal provide a window into the framework we have been working toward as we leverage our capital investments in our Augusta facility for the white label opportunity. We are set to receive strong demand at strong terms, including compensation for high-volume production of our premium CBD Oil output as well as our bottling technology.
In all, just in the first of these planned orders, we will receive a substantial revenue input, with no costs associated with bottling, labeling, or shipping of the final product.
Eagle Hemp is just one of many customers currently in play for our premium product output. The CBD market is turning out to be every bit the juggernaut that the major analyst firms have been suggesting over the past year. Estimates now range from several hundred to several thousand percentage points of gross sales expansion in the space over the next 36-48 months, which is a reasonable definition of boom conditions for a major industry in robust infancy.
The driver here, as we have elaborated in past communications, is about the seemingly bottomless demand growth function that accompanies the evolution of a product category from fringe consumer niche to mainstream adoption.
It is also important to note that we continue to receive requests from other industry customers and we are in the process of investigating the credibility of such requests and in negotiating similar terms for concrete relationships.
In addition, our production facility and lab are running along in amazing fashion. We now have two bottling machines active and operational due to the tremendous interest coming in the door. Once we have distilled this interest into official purchase orders, we will divulge them in our communications.
We also want to announce that our vaping machine is active and fully operational, we are now ready to produce and sell CBD vapes.
Finally, as we continue to expand, diversify, and integrate, we are now also working on plans to build a greenhouse dedicated to cultivating super-enriched seeds. We have always been committed to the long-term goal of fully controlling our production ecosystem from seed to product, and this is the next step in establishing that fully vertical model, where we see the strongest margins.
Best Regards,
Salvador Rosillo
As you can see, this is a company built for growth, and at just $0.007 per share, this could be one of the biggest steals in the entire cannabis sector.
Market Outlook for CBD:
New projections from the Brightfield Group in its June report suggest, if anything, a further acceleration in the overall growth of the CBD space, and some suggestion that this acceleration is being driven by an increasingly tangible jump in mainstream consumer adoption of CBD-based products. Specifically, the report notes that 2019 will show a 700% jump relative to 2018 levels for all domestic sales of CBD-based products, with 2019 on pace to exceed $5 billion in total sales of products containing CBD given current data. In addition, according to the Brightfield Group researchers, much of this jump will be due to sales in mainstream retail chain stores.
The cannabis market has grown at a tremendous pace over the recent years and as such, the industry has established itself a major global market. According to data compiled by Grand View Research, the global legal cannabis market is projected to reach USD 146.4 Billion by the 2025. It is also expected to grow at a CAGR of 34.6%. The market itself is witnessing a widespread legalization movement due to the growing adoption of the plant within the medical sector. Cannabis is being used heavily around the global for medical applications and treatments for maladies such as cancer, mental disorders, chronic pain, and others. However, the recreational market is thriving as well due specifically to the U.S. and Canada. States like California, Colorado, and Nevada are expected to propel the recreational sector forward at an encouraging rate.
The acceleration of research and development has led to new products within the market, enhancing consumer experiences. The research suggests that the industry is expecting strong exchanges of technological knowledge and information. Meanwhile, as countries like Canada, the U.S., Germany, and Australia lead the market in sales, countries like Israel are focusing on research and technology development to further expand within the industry. Additionally, there are various new forms of technology being introduced into the cannabis sector, such as virtual reality, payment solutions, and medical devices. "That's why we firmly believe that technology stands at the center of the industry's advancement and growth," said Ben Curren Chief Executive Officer of Green Bits, "This innovation will continue to generate market growth, improve public perception, protect public health and safety and enhance the implementation of state programs and regulations.
CBD is becoming widely accepted by consumers and countries. For example, in the U.S., CBD became legal after the Farm Bill that passed in late 2018.
That in mind, consumers could easily find CBD products across the U.S. In turn, we may actually see some CBD companies generating more revenues and earnings than cannabis companies.
Now, investment bank Cowen & Co. analysts estimate that the CBD market will reach $16B by 2025.
That said, CBD companies could experience exponential growth rates with such a large market. Not only that, large-cap drug stores like CVS and Walgreens have bet on CBD .
Additionally, CVS and Walgreens noted they would offer CBD products in more than 2,000 stores across the U.S.
Technical Analysis
Subpenny Stocks = Big Moves
We love these subpenny alerts because even the smallest move can result in massive gains for traders.
As we mentioned above, HMPQ is sitting on a bottom'd out chart with plenty of room to the upside.
We love these type of alerts because the downside risk appears minimal, but the upside is almost too good to ignore.
HMPQ is trading well off its 52-week of $0.0277.
A run back to those levels would net traders nearly +300% in profit from today's alert price.
We've done our very own chart analysis and see the potential for an explosive move in the very near future.
The Bottom-Line
We've been right on the money with our most recent cannabis sector alerts.
HMPQ is exactly the type of alert that we look for. Undervalued with major growth potential.
These are the types of alerts that offer traders the biggest payoff potential.
This could be our next subpenny alert to double in price, so make sure you have it on your radar!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated seventeen thousand five hundred dollars by One 22 Media LLC to conduct a one-day investor relations advertising and marketing campaign and 1,500 Trading View™ views for HMPQ. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Jul 29
Comment: CORRECTION
=====================
HempAmericana, Inc (HMPQ)
Alert Price: $0.007
========================
BTC Golden Crossover ON 3 Day Chart Incoming!
Here we have it. Possible upside move after this possible retracement. Be patent but we look like a collision course for the golden crossover is upon us for Bitcoin .
We believe from Q4 Bitcoin and the whole market will pick up with the Bitcoin Halving hype taking over.
BTC Golden Crossover ON 3 Day Chart Incoming!
Here we have it. Possible upside move after this possible retracement. Be patent but we look like a collision course for the golden crossover is upon us for Bitcoin .
We believe from Q4 Bitcoin and the whole market will pick up with the Bitcoin Halving hype taking over.
BTC - Are We Going Towards $8K?
3 Daily chart is looking towards that $8300 region as possible support. We feel that once 9400 is lost we may see a drop into that $8K regions.
Don't rush in just yet. Still have an indecisive (current) candle to worry about. Wait and see how we close and go from there post-weekend and opening weekly candle.
BTC - Are We Going Towards $8K?
3 Daily chart is looking towards that $8300 region as possible support. We feel that once 9400 is lost we may see a drop into that $8K regions.
Don't rush in just yet. Still have an indecisive (current) candle to worry about. Wait and see how we close and go from there post-weekend and opening weekly candle.
TWOH is our bottom'd chart bounce alert, Tremendous Potential.
=====================
TWOH (Two Hands Corporation)
Alert Price: $0.04
Float: 80.45M
Website | Recent News
========================
Members,
There is an enormous and historic process underway that has defining implications for investors over the next decade and beyond, and Two Hands Corp (OTCQB:TWOH) has been paying attention. As we detail below, keep in mind the huge stores of investment potential being accumulated by younger millennials who have yet to mobilize in large numbers in the financial market landscape.
The process that we are talking about here is the adoption by mainstream consumers of the cannabis plant and all of its products.
Two Businesses In One
TWOH is essentially two businesses in one.
Not only is the company focusing on the lucrative CBD arena, but also the app arena. Both are multi-billion dollar sectors with tremendous growth potential in front of them.
Diversification is an integral part of any successful business, and TWOH has that covered and then some.
TWOH's Corporate Update Paints A Bright Picture For The Future
Last Tuesday, TWOH released their most recent corporate update, and let's just say the future's so bright you got to wear shades!
Highlights from the Update Include:
Making solid progress to growing their CBD business and listing on The Canadian Securities Exchange.
Anticipate their initial test harvests comprised of 10 different genetic strains and nearly 600 plants will be evaluated by the ICA in the coming weeks so they can continue construction of their Greenhouses as they continue to invest and advance their cannabis cultivation footprint up to the 10 hectares over the next twelve to eighteen months after the closing. As they continue to expand their business, they have initiated talks to acquire another licence within Central Africa
About Two Hands Corporation
Two Hands Group is a custom application development and medical technologies company that strives to create complete solutions. Our ultimate goal is to provide quality products that are innovative and meet and exceed the needs of our customers. Our Co-Parenting App is the ideal solution to reduce the stress and worries of families affected by divorce. Our Gone App allows you to send encrypted text messages right from your phone, combining military-grade security, confidentiality, and privacy – with the utmost convenience, right at your fingertips. Two Hands Corp Lab is an organic hemp based CBD cultivator located in Colombia. They are vertically integrated, producing from seed to wholesaler.
Divisions
Two Hands Co-parenting App
Two Hands Co-parenting App is the product of years of searching for the ideal solution that will reduce the stress and worries of co-parenting. This application fulfills our mission and vision that focuses on organization and communication to improve family relationships despite a divorce.
Two Hands Gone
Two Hands Gone allows you to send encrypted text messages right from your phone, combining military-grade security, confidentiality, and privacy – with the utmost convenience, right at your fingertips.
Two Hands Corp Lab
Two Hands Corp Lab is an organic hemp based CBD cultivator located in Colombia. We are vertically integrated, producing from seed to wholesaler. We will create the highest quality CBD extract derivatives to exported and purchased.
TWOH's Two Hands app is a co-parenting app that could become one of the go to apps for parents all around!
After years of collaborating with fellow parents and co-parents, and through the help of their designers and programmers, “Two Hands” was conceived.
It has all the important features that any parent, co-parent or caregiver would ever need to deal with any kind of activity concerning children.
The app was designed to reduce the stress and worries of co-parenting.
Imagine having a tool that lets both father and mother have access to all of their children's information, and appointments in one place.
TWOH's “Two Hands” is accessed primarily through the web which makes it easier to connect to people and manage one or two households at the same time but the company has also made it possible for the application to be accessed from all kinds of devices and have made it easier to understand even for someone who is not that tech savvy.
The application will allow parents to track and assign activities that their child is apart of, as well as offer a shared custody calander, to avoid any confusion on what is going on what date. You can store files as well and easily share them. This includes photos, and medical records, as well as travel documents and passwords.
TWOH also recently launched its newest application "Two Hands Gone."
For some people, privacy and confidentiality with text messaging is a priority. There are just some messages that are not meant for wandering eyes and the company's app offers a service that allows messages to be read and then disappear completely. Screenshots of conversations are restricted, and messages expire 45 seconds after being read.
Capitalizing On The CBD Boom With TWOH
The most important part of this opportunity is the overall forward outlook for the CBD market, which is unambiguously experiencing a boom with the lion’s share of the upside still on the way.
According to new data and research released by the Brightfield Group, sales of products containing CBD are expected top $5 billion this year alone. That’s an incredible 700% year/year increase.
The passage of the US Farm Bill in December is a big catalyst in this story. The bill contained language extremely favorable to the legal hemp industry and to those ready to invest in the CBD boom. Since that time, we’ve seen CBD products hit the shelves of drug stores and grocers, and pop up on fast food menus.
Product differentiation is also a big part of the story. CBD is now a multi-billion growth industry with ties into the pet care, sports drinks, cosmetics, and medical industries, to name but a few. It is also now FDA approved as a treatment for rare seizure disorders.
There are major catalysts ahead that may help to infuse even faster growth into the picture. For example, the FDA held a public hearing in late May of this year on CBD and its potential benefits, and we are now in public comment phase that will wrap up in mid-July. The result could be an even bigger boost pushing more mainstream consumer adoption of CBD-based products.
Brightfield’s analysis puts the 2023 level in line with Statista’s, at around $23-24B in total sales, with most of those sales likely to come from big chain retailers. In other words, the CBD boom is about to move out of the backwaters of niche e-commerce websites and into mainstream daily life.
The first wave of this adoption process clearly centers around hemp-based cannabidiol ( CBD ), which is already legal in all 50 US states and has already found its way into many different consumer product categories, including skin creams, beverages, supplements, and vapes.
While we have seen enormous growth in the CBD space, Wall Street analysts believe we have only seen the tip of the iceberg. In fact, a recent Statista research report now projects the total CBD market will hit $23 billion total by 2023, representing a 20-fold increase over the next 4 years.
To add further fuel to the fire, the US Federal Government is starting to become a tailwind – as a case in point, Senators Dianne Feinstein (D-Calif.), Chuck Grassley (R-Iowa), and Brian Schatz (D-Hawaii) submitted the new Senate bill, “The Cannabidiol and Marijuana Research Expansion Act”, at the end of June. This suggests the trend toward increasing legislative acceptance continues and is likely accelerating with key long-term implications.
Perhaps the most interesting way to capitalize on this opportunity is to find new emerging vertically integrated CBD producers positioned to deliver outsized margins on a per-weight production basis, which is why we now turn our attention to one such opportunity in particular: Two Hands Corp (OTCQB:TWOH).
TWOH's Colombian Connection
In late June, TWOH agreed to purchase 100% of the licence to grow, export, hold cannabis and CBD derivatives in Colombia from Plantro Inc S.A.S. Once the genetics have been approved and the remainder of the conditions placed on Plantro S.A.S. are satisfied we expect to close the transaction and utilize the licence to its full potential.
CEO of Two Hands, Nadav Elituv commented, “As part of our agreement the Plantro S.A.S. team has been assisting with the initial construction of our Greenhouses on the first hectare located in the center of Bogota Savannah in Madrid, Colombia. The greenhouses now house the initial test harvests of nearly 600 plants comprised of 10 different genetic strains to be evaluated by the ICA .
They will continue to invest and advance our cannabis cultivation footprint up to the 10 hectares over the next twelve to eighteen months after the transaction closes. The first seed sowing took place the end of April 2019, and currently our first plants have started to grow. You can have a look at https://www.twohandsgroup.com/twohandsco...
Colombia is an ideal location for a major CBD production base. It offers optimal growing conditions, low labor costs, and a very stable pro-cannabis government.
Two Hands has completed construction on two state-of-the-art greenhouses, each of which is expected to go into full operation upon final approval, cost about $35,000 USD to construct, and hit a full financial breakeven point – in terms of all-in costs – after a single harvest.
Could TWOH Be Setting Up For It's Next Triple-Digit Move?
TWOH has been a very exciting ticker to watch to say the least.
Last week TWOH saw its share price more than double from $0.0405 to $0.10.
TWOH has now once again retraced back to historic support, and may offer substantial upside at these levels.
Based on our very own chart analysis above, we see the potential for another move back to $0.10, which at these levels would show a ROI of over +100%!
The Bottom-Line
TWOH has already shown us its ability to double in price in a very short amount of time.
TWOH is once again trading in that sweet spot, and we believe that now could be the perfect time to start building a position.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. One 22 Media LLC has compensated us up to $1,500 per day for 1,500 Trading View™ views per day for the next 7 days for advertising and marketing services for TWOH. We have previously been compensated seventeen thousand five hundred dollars by One 22 Media LLC to conduct a one-day investor relations advertising and marketing campaign and 2,000 Trading View™ views for TWOH -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
TWOH is our bottom'd chart bounce alert, Tremendous Potential.
=====================
TWOH (Two Hands Corporation)
Alert Price: $0.04
Float: 80.45M
Website | Recent News
========================
Members,
There is an enormous and historic process underway that has defining implications for investors over the next decade and beyond, and Two Hands Corp (OTCQB:TWOH) has been paying attention. As we detail below, keep in mind the huge stores of investment potential being accumulated by younger millennials who have yet to mobilize in large numbers in the financial market landscape.
The process that we are talking about here is the adoption by mainstream consumers of the cannabis plant and all of its products.
Two Businesses In One
TWOH is essentially two businesses in one.
Not only is the company focusing on the lucrative CBD arena, but also the app arena. Both are multi-billion dollar sectors with tremendous growth potential in front of them.
Diversification is an integral part of any successful business, and TWOH has that covered and then some.
TWOH's Corporate Update Paints A Bright Picture For The Future
Last Tuesday, TWOH released their most recent corporate update, and let's just say the future's so bright you got to wear shades!
Highlights from the Update Include:
Making solid progress to growing their CBD business and listing on The Canadian Securities Exchange.
Anticipate their initial test harvests comprised of 10 different genetic strains and nearly 600 plants will be evaluated by the ICA in the coming weeks so they can continue construction of their Greenhouses as they continue to invest and advance their cannabis cultivation footprint up to the 10 hectares over the next twelve to eighteen months after the closing. As they continue to expand their business, they have initiated talks to acquire another licence within Central Africa
About Two Hands Corporation
Two Hands Group is a custom application development and medical technologies company that strives to create complete solutions. Our ultimate goal is to provide quality products that are innovative and meet and exceed the needs of our customers. Our Co-Parenting App is the ideal solution to reduce the stress and worries of families affected by divorce. Our Gone App allows you to send encrypted text messages right from your phone, combining military-grade security, confidentiality, and privacy – with the utmost convenience, right at your fingertips. Two Hands Corp Lab is an organic hemp based CBD cultivator located in Colombia. They are vertically integrated, producing from seed to wholesaler.
Divisions
Two Hands Co-parenting App
Two Hands Co-parenting App is the product of years of searching for the ideal solution that will reduce the stress and worries of co-parenting. This application fulfills our mission and vision that focuses on organization and communication to improve family relationships despite a divorce.
Two Hands Gone
Two Hands Gone allows you to send encrypted text messages right from your phone, combining military-grade security, confidentiality, and privacy – with the utmost convenience, right at your fingertips.
Two Hands Corp Lab
Two Hands Corp Lab is an organic hemp based CBD cultivator located in Colombia. We are vertically integrated, producing from seed to wholesaler. We will create the highest quality CBD extract derivatives to exported and purchased.
TWOH's Two Hands app is a co-parenting app that could become one of the go to apps for parents all around!
After years of collaborating with fellow parents and co-parents, and through the help of their designers and programmers, “Two Hands” was conceived.
It has all the important features that any parent, co-parent or caregiver would ever need to deal with any kind of activity concerning children.
The app was designed to reduce the stress and worries of co-parenting.
Imagine having a tool that lets both father and mother have access to all of their children's information, and appointments in one place.
TWOH's “Two Hands” is accessed primarily through the web which makes it easier to connect to people and manage one or two households at the same time but the company has also made it possible for the application to be accessed from all kinds of devices and have made it easier to understand even for someone who is not that tech savvy.
The application will allow parents to track and assign activities that their child is apart of, as well as offer a shared custody calander, to avoid any confusion on what is going on what date. You can store files as well and easily share them. This includes photos, and medical records, as well as travel documents and passwords.
TWOH also recently launched its newest application "Two Hands Gone."
For some people, privacy and confidentiality with text messaging is a priority. There are just some messages that are not meant for wandering eyes and the company's app offers a service that allows messages to be read and then disappear completely. Screenshots of conversations are restricted, and messages expire 45 seconds after being read.
Capitalizing On The CBD Boom With TWOH
The most important part of this opportunity is the overall forward outlook for the CBD market, which is unambiguously experiencing a boom with the lion’s share of the upside still on the way.
According to new data and research released by the Brightfield Group, sales of products containing CBD are expected top $5 billion this year alone. That’s an incredible 700% year/year increase.
The passage of the US Farm Bill in December is a big catalyst in this story. The bill contained language extremely favorable to the legal hemp industry and to those ready to invest in the CBD boom. Since that time, we’ve seen CBD products hit the shelves of drug stores and grocers, and pop up on fast food menus.
Product differentiation is also a big part of the story. CBD is now a multi-billion growth industry with ties into the pet care, sports drinks, cosmetics, and medical industries, to name but a few. It is also now FDA approved as a treatment for rare seizure disorders.
There are major catalysts ahead that may help to infuse even faster growth into the picture. For example, the FDA held a public hearing in late May of this year on CBD and its potential benefits, and we are now in public comment phase that will wrap up in mid-July. The result could be an even bigger boost pushing more mainstream consumer adoption of CBD-based products.
Brightfield’s analysis puts the 2023 level in line with Statista’s, at around $23-24B in total sales, with most of those sales likely to come from big chain retailers. In other words, the CBD boom is about to move out of the backwaters of niche e-commerce websites and into mainstream daily life.
The first wave of this adoption process clearly centers around hemp-based cannabidiol ( CBD ), which is already legal in all 50 US states and has already found its way into many different consumer product categories, including skin creams, beverages, supplements, and vapes.
While we have seen enormous growth in the CBD space, Wall Street analysts believe we have only seen the tip of the iceberg. In fact, a recent Statista research report now projects the total CBD market will hit $23 billion total by 2023, representing a 20-fold increase over the next 4 years.
To add further fuel to the fire, the US Federal Government is starting to become a tailwind – as a case in point, Senators Dianne Feinstein (D-Calif.), Chuck Grassley (R-Iowa), and Brian Schatz (D-Hawaii) submitted the new Senate bill, “The Cannabidiol and Marijuana Research Expansion Act”, at the end of June. This suggests the trend toward increasing legislative acceptance continues and is likely accelerating with key long-term implications.
Perhaps the most interesting way to capitalize on this opportunity is to find new emerging vertically integrated CBD producers positioned to deliver outsized margins on a per-weight production basis, which is why we now turn our attention to one such opportunity in particular: Two Hands Corp (OTCQB:TWOH).
TWOH's Colombian Connection
In late June, TWOH agreed to purchase 100% of the licence to grow, export, hold cannabis and CBD derivatives in Colombia from Plantro Inc S.A.S. Once the genetics have been approved and the remainder of the conditions placed on Plantro S.A.S. are satisfied we expect to close the transaction and utilize the licence to its full potential.
CEO of Two Hands, Nadav Elituv commented, “As part of our agreement the Plantro S.A.S. team has been assisting with the initial construction of our Greenhouses on the first hectare located in the center of Bogota Savannah in Madrid, Colombia. The greenhouses now house the initial test harvests of nearly 600 plants comprised of 10 different genetic strains to be evaluated by the ICA .
They will continue to invest and advance our cannabis cultivation footprint up to the 10 hectares over the next twelve to eighteen months after the transaction closes. The first seed sowing took place the end of April 2019, and currently our first plants have started to grow. You can have a look at https://www.twohandsgroup.com/twohandsco...
Colombia is an ideal location for a major CBD production base. It offers optimal growing conditions, low labor costs, and a very stable pro-cannabis government.
Two Hands has completed construction on two state-of-the-art greenhouses, each of which is expected to go into full operation upon final approval, cost about $35,000 USD to construct, and hit a full financial breakeven point – in terms of all-in costs – after a single harvest.
Could TWOH Be Setting Up For It's Next Triple-Digit Move?
TWOH has been a very exciting ticker to watch to say the least.
Last week TWOH saw its share price more than double from $0.0405 to $0.10.
TWOH has now once again retraced back to historic support, and may offer substantial upside at these levels.
Based on our very own chart analysis above, we see the potential for another move back to $0.10, which at these levels would show a ROI of over +100%!
The Bottom-Line
TWOH has already shown us its ability to double in price in a very short amount of time.
TWOH is once again trading in that sweet spot, and we believe that now could be the perfect time to start building a position.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. One 22 Media LLC has compensated us up to $1,500 per day for 1,500 Trading View™ views per day for the next 7 days for advertising and marketing services for TWOH. We have previously been compensated seventeen thousand five hundred dollars by One 22 Media LLC to conduct a one-day investor relations advertising and marketing campaign and 2,000 Trading View™ views for TWOH -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
THM - Risky Move - Trend Is Strong. Still Gains To Be Had
International Tower Hill Mines Ltd.is a mineral exploration company. The Company is in the business of acquiring, exploring and evaluating mineral properties, and either joint venturing or developing these properties further or disposing of them when the evaluation is completed. It operates through the exploration and development of mineral properties segment. The Company owns the Livengood Gold Project in Alaska, the United States. The Livengood Gold Project is located approximately 70 miles northwest of Fairbanks, Alaska in the Tolovana mining district within the Tintina Gold Belt. The Livengood Gold Project has a mineral resource of approximately 730 million measured tons at an average grade of over 0.61 gram/ton (g/ton), approximately 70 million indicated tons at an average grade of approximately 0.56 g/ton and over 260 million inferred tons at an average grade of approximately 0.52 g/ton.
SHORT INTEREST
653.75K 07/15/19
P/E Current
-26.79
P/E Ratio (with extraordinary items)
-28.91
THM - Risky Move - Trend Is Strong. Still Gains To Be Had
International Tower Hill Mines Ltd.is a mineral exploration company. The Company is in the business of acquiring, exploring and evaluating mineral properties, and either joint venturing or developing these properties further or disposing of them when the evaluation is completed. It operates through the exploration and development of mineral properties segment. The Company owns the Livengood Gold Project in Alaska, the United States. The Livengood Gold Project is located approximately 70 miles northwest of Fairbanks, Alaska in the Tolovana mining district within the Tintina Gold Belt. The Livengood Gold Project has a mineral resource of approximately 730 million measured tons at an average grade of over 0.61 gram/ton (g/ton), approximately 70 million indicated tons at an average grade of approximately 0.56 g/ton and over 260 million inferred tons at an average grade of approximately 0.52 g/ton.
SHORT INTEREST
653.75K 07/15/19
P/E Current
-26.79
P/E Ratio (with extraordinary items)
-28.91
ENSV - Increasing Volume + Media Presence. Resistance Test Due!
Enservco Corporation provides well and fluid management services to the domestic onshore oil and natural gas industry. The Company's services include frac water heating, hot oiling and acidizing (well enhancement services), and water transfer, water treatment, water hauling, fluid disposal, frac tank rental (fluid management services) and other general oilfield services. Well enhancement services consist of frac water heating, acidizing, hot oiling services and pressure testing. These services are provided by its subsidiary, Heat Waves Hot Oil Service LLC (Heat Waves), which utilize a fleet of approximately 200 custom designed trucks and other related equipment. The Company owns or leases, and operates approximately 65 water-hauling trucks and trailers equipped with pumps to move water from or into wells, tanks and other storage facilities. Each truck has a hauling capacity of approximately 130 barrels. It also provides well-site construction and roustabout services.
SHORT INTEREST
464.49K 07/15/19
P/E Current
-4.11
P/E Ratio (with extraordinary items)
-6.99
Average Recommendation: BUY
Average Target Price: 1.33